Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Merck
Express Scripts
US Army
Queensland Health
Federal Trade Commission
QuintilesIMS
Healthtrust
Covington
Cipla

Generated: April 19, 2018

DrugPatentWatch Database Preview

Vale Company Profile

« Back to Dashboard

Summary for Vale
International Patents:269
US Patents:40
Tradenames:103
Ingredients:80
NDAs:128

Drugs and US Patents for Vale

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Valeant Pharms North TIAZAC diltiazem hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 020401-002 Sep 11, 1995 AB4 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial
Valeant Pharms Intl COLAZAL balsalazide disodium CAPSULE;ORAL 020610-001 Jul 18, 2000 AB RX Yes Yes 7,625,884*PED ➤ Try a Free Trial Y ➤ Try a Free Trial
Valeant PHRENILIN FORTE acetaminophen; butalbital CAPSULE;ORAL 088831-001 Jun 19, 1985 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial
Valeant Intl RETIN-A MICRO tretinoin GEL;TOPICAL 020475-001 Feb 7, 1997 AB RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for Vale

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Valeant Pharms North RENOVA tretinoin CREAM;TOPICAL 021108-001 Aug 31, 2000 RE36068 ➤ Try a Free Trial
Valeant Intl RETIN-A tretinoin SOLUTION;TOPICAL 016921-001 Approved Prior to Jan 1, 1982 3,729,568 ➤ Try a Free Trial
Valeant Luxembourg VISUDYNE verteporfin INJECTABLE;INJECTION 021119-001 Apr 12, 2000 5,707,608 ➤ Try a Free Trial
Valeant MIGRANAL dihydroergotamine mesylate SPRAY, METERED;NASAL 020148-001 Dec 8, 1997 5,169,849 ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for VALE drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Cream 0.5% ➤ Subscribe 2011-07-29
➤ Subscribe Extended-release Tablets 150 mg and 300 mg ➤ Subscribe 2004-09-21
➤ Subscribe Tablets 1.1 g ➤ Subscribe 2013-11-05
➤ Subscribe Rectal Gel 5 mg/mL, 4mL pre-filled syringe ➤ Subscribe 2008-12-08
➤ Subscribe Extended-release Tablets 9 mg ➤ Subscribe 2013-03-11
➤ Subscribe Extended-release Tablets 120 mg, 180 mg, 240 mg, 300 mg and 360 mg ➤ Subscribe 2005-08-30
➤ Subscribe Extended-release Tablets 100 mg ➤ Subscribe 2007-01-08
➤ Subscribe Extended-release Tablets 300 mg ➤ Subscribe 2007-09-25
➤ Subscribe Extended-release Tablets 348 mg ➤ Subscribe 2009-09-24
➤ Subscribe Gel 0.1% ➤ Subscribe 2010-07-08
➤ Subscribe Capsules 75 mg ➤ Subscribe 2011-06-06
➤ Subscribe Extended-release Capsules 0.375 g ➤ Subscribe 2012-04-03
➤ Subscribe Rectal Gel 2.5 mg/0.5 mL, 5 mg/mL, 10 mg/2 mL, 15 mg/3 mL and 20 mg/4 mL ➤ Subscribe 2004-03-23
➤ Subscribe For Inhalation Solution 6 gm/vial ➤ Subscribe 2014-05-22
➤ Subscribe Rectal Gel 5 mg/mL, 2mL pre-filled syringe ➤ Subscribe 2008-12-23
➤ Subscribe Extended-release Tablets 420 mg ➤ Subscribe 2005-04-25
➤ Subscribe Extended-release Tablets 200 mg ➤ Subscribe 2007-03-28
➤ Subscribe Extended-release Tablets 174 mg ➤ Subscribe 2009-09-28
➤ Subscribe Extended-release Tablets 522 mg ➤ Subscribe 2009-12-24
➤ Subscribe Gel 0.04% ➤ Subscribe 2010-12-20
Premature patent expirations for VALE

Expiration due to failure to pay maintenance fee

Patent Number Expiration Date
➤ Try a Free Trial ➤ Try a Free Trial

Non-Orange Book US Patents for Vale

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,547,451 Pellet formulation for the treatment of the intestinal tract ➤ Try a Free Trial
7,553,992 Modified release formulations of a bupropion salt ➤ Try a Free Trial
7,563,823 Modified release formulations of a bupropion salt ➤ Try a Free Trial
6,143,327 Delayed release coated tablet of bupropion hydrochloride ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Supplementary Protection Certificates for Vale Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB98/003 United Kingdom ➤ Try a Free Trial PRODUCT NAME: DESIRUDIN, OR A SALT THEREOF; REGISTERED: UK EU/1/97/043/001 19970709; UK EU/1/97/043/002 19970709
00037 Netherlands ➤ Try a Free Trial PRODUCT NAME: VERTEPORFINE, DESGEWENST IN DE VORM VAN EEN ZOUT; REGISTRATION NO/DATE: EU/1/00/140/001 20000727
/2003 Austria ➤ Try a Free Trial PRODUCT NAME: PIMECROLIMUS, GEGEBENENFALLS IN FORM PHARMAZEUTISCH ANNEHMBARER SALZE; NAT. REGISTRATION NO/DATE: 1-24689 20020917; FIRST REGISTRATION: DK 21034 20020315
2001 Austria ➤ Try a Free Trial PRODUCT NAME: VERTEPORFIN; REGISTRATION NO/DATE: EU/1/00/140/001 20000727
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Farmers Insurance
Daiichi Sankyo
Chubb
Queensland Health
Express Scripts
Julphar
Deloitte
McKesson
US Army

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.